- Home
- RMI vs WHWK Comparison
RMI vs WHWK Comparison
Compare RMI & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMI | WHWK |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.9M | 95.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMI | WHWK |
|---|---|---|
| Price | $15.67 | $4.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 56.5K | ★ 135.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.63 | $1.39 |
| 52 Week High | $16.36 | $3.94 |
Technical Indicators
Market Signals| Indicator | RMI | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 76.52 |
| Support Level | $14.15 | $1.84 |
| Resistance Level | $16.36 | N/A |
| Average True Range (ATR) | 0.37 | 0.23 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 43.33 | 99.16 |
Price Performance
Historical ComparisonAbout RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.